Pfizer signs deal to expand access to its COVID-19 oral antiviral treatment

Pfizer, Medicines Patent Pool

Pfizer, Medicines Patent Pool sign agreement. MPP to sub-license Pfizer’s COVID-19 antiviral drug.

Where: NY and Geneva

The Facts

On November 16th, Pfizer and the Medicines Patent Pool (MPP) signed a voluntary licensing agreement for the former’s COVID-19 oral antiviral treatment drug.

The license agreement will grant easy and affordable access to Pfizer’s antiviral treatment in low-to-middle-income countries (LMICs), pending regulatory authorization.

The agreement allows the MPP to issue sub-licenses for the production and distribution of the investigational drug to eligible generic medicines manufacturers, to facilitate greater global access to the treatment.

Pfizer CEO, Albert Bourla, added that the company would not receive royalties from sales of the antiviral drug in low-income countries.

Pfizer will also waive royalties on sales in all countries included in the agreement if the WHO reclassifies COVID-19 as a Public Health Emergency of International Concern.

MPP Executive Director, Charles Gore, stated that the drug could play a “critical role in saving lives and aid global efforts to combat the COVID-19 pandemic”.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.